Search
Close this search box.

Treating obesity by quelling inflammation in the brain

ARTICLE | Product Development

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone

By Stephen Hansen, Director of Biopharma Intelligence

March 18, 2024 10:40 PM UTC

Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than GLP-1s and an improved cardioprotective profile. But investors shouldn’t expect to see efficacy as quickly for the anti-inflammatory mechanism as observed with incretin-based therapies.

The NLRP3 inflammasome has been implicated as a driver of pathology in a variety of diseases, ranging from cancer to asthma, heart disease and metabolic-associated steatohepatitis (MASH)…